Last reviewed · How we verify

Prasugrel or Clopidogrel

University of Patras · FDA-approved active Small molecule Quality 5/100

Prasugrel or Clopidogrel is a Small molecule drug developed by University of Patras. It is currently FDA-approved.

At a glance

Generic namePrasugrel or Clopidogrel
SponsorUniversity of Patras
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Prasugrel or Clopidogrel

What is Prasugrel or Clopidogrel?

Prasugrel or Clopidogrel is a Small molecule drug developed by University of Patras.

Who makes Prasugrel or Clopidogrel?

Prasugrel or Clopidogrel is developed and marketed by University of Patras (see full University of Patras pipeline at /company/university-of-patras).

What development phase is Prasugrel or Clopidogrel in?

Prasugrel or Clopidogrel is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing